Phase I CARLYSLE trial data show CAR-T therapy obe-cel induces remission in severe refractory lupus with a favorable safety profile. Separate case report documents two successful pregnancies after dual-target CAR-T therapy with no transmission to infants.
Updated data from the phase I CaMMouflage trial showed CB-011, the first allogeneic anti-BCMA CAR-T therapy with immune cloaking, achieved an approximately 92% overall response rate in relapsed/refractory multiple myeloma. The 2026 Tandem Meetings also highlighted advances in EB-103, KITE-753, and LV20.19 CAR-T constructs across lymphoma and CLL. Separately, NXC-201 reported a 95% complete response rate in AL amyloidosis.
The FDA approved Bristol Myers Squibb’s Breyanzi for adults with relapsed or refractory marginal zone lymphoma after at least two prior systemic therapies. In TRANSCEND FL, the CAR T therapy showed a 95.5% overall response rate and 62.1% complete response rate.
The FDA approved oral decitabine and cedazuridine tablets plus venetoclax for newly diagnosed AML in patients 75 and older or those ineligible for intensive induction chemotherapy. The approval was supported by phase 1/2 ASTX727-07 data showing a 41.6% complete response rate.
CAR-T toxicity management is shifting toward phenotype- and mechanism-based intervention. Key issues include CRS, ICANS, IEC-HS, and long-term risks of cytopenia and infection.
Citius Pharmaceuticals reported $3.9 million in first revenue from LYMPHIR's December 2025 launch for cutaneous T-cell lymphoma, while subsidiary Citius Oncology announced positive Phase 1 data showing 86% response rate when LYMPHIR was administered prior to CAR-T therapy in high-risk lymphoma patients.
Researchers develop multiple strategies to enhance CAR T-cell therapy, including dual PGE2 receptor knockout for solid tumors and small-molecule switches using venetoclax and caffeine to control cellular activity and improve safety.
Recent advances in chimeric antigen receptor cell therapies highlight improved designs for CAR-T and CAR-NK treatments, with new strategies addressing efficacy and safety challenges in both hematologic and solid tumors.
New research demonstrates that dexamethasone effectively ameliorates cytokine-release syndrome in CAR T-cell therapy for multiple myeloma while maintaining or enhancing anti-tumor activity and increasing CAR T-cell levels.
T-cell immunotherapies including CAR T-cell therapy and T-cell engagers are expanding cancer treatment options but present significant cardiovascular risks and operational complexities requiring coordinated multidisciplinary management.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05474924 |
The Role of Budesonide Intrapolyp Injection in CRSwNP |
UNKNOWN | PHASE4 |
| NCT04868695 |
Subjective and Objective Outcome of ESS in CRSwNP |
RECRUITING | NA |
| NCT03379701 |
Applications of Nanotechnology and Chemical Sensors for the Detection and Identification of Chronic Sinusitis Subtypes by Respiratory Samples |
COMPLETED | |
| NCT02997020 |
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis (EDSPD Protocol) |
ACTIVE_NOT_RECRUITING |
